Home  |  Contact

Cellosaurus MR49F (CVCL_RW53)

[Text version]

Cell line name MR49F
Synonyms MR49-F; ENZR 49F; 49FENZR
Accession CVCL_RW53
Resource Identification Initiative To cite this cell line use: MR49F (RRID:CVCL_RW53)
Comments Selected for resistance to: ChEBI; CHEBI:68534; Enzalutamide (Xtandi; MDV-3100).
Sequence variations Homozygous for AR p.Thr878Ala (c.2632A>G) (from parent cell line).
Heterozygous for MEN1 p.Tyr313Ter (c.939T>A) (from parent cell line).
Heterozygous for PIK3R1 p.Arg639Ter (c.1915C>T) (from parent cell line).
PTEN p.Lys6Argfs*4 (c.17_18delAA) (from parent cell line).
Disease Prostate carcinoma (NCIt: C4863)
Derived from metastatic site: Left supraclavicular lymph node.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0395 (LNCaP)
Sex of cell Male
Age at sampling 50Y
Category Cancer cell line

PubMed=25428917; DOI=10.18632/oncotarget.2703
Bishop J.L., Sio A., Angeles A., Roberts M.E., Azad A.A., Chi K.N., Zoubeidi A.
PD-L1 is highly expressed in Enzalutamide resistant prostate cancer.
Oncotarget 6:234-242(2015)

PubMed=25634993; DOI=10.1158/1078-0432.CCR-14-1108
Yamamoto Y., Loriot Y., Beraldi E., Zhang F., Wyatt A.W., Al Nakouzi N., Mo F., Zhou T., Kim Y., Monia B.P., MacLeod A.R., Fazli L., Wang Y., Collins C.C., Zoubeidi A., Gleave M.
Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.
Clin. Cancer Res. 21:1675-1687(2015)

Other Wikidata; Q54906576
Entry history
Entry creation05-Mar-2018
Last entry update02-Jul-2020
Version number4